-
(单词翻译:双击或拖选)
WASHINGTON, Jan. 14 (Xinhua) -- The U.S. Food and Drug Administration said Wednesday it had approved the first device to treat obesity1 by targeting nerves between the brain and the stomach.
The device, known as the Maestro Rechargeable System, is approved to treat patients aged2 18 and older who have not been able to lose weight with a weight loss program, and who have a body mass index (BMI) of 35 to 45 with at least one other obesity- related condition, such as type 2 diabetes3.
BMI, which measures body fat based on an individual's weight and height, is used to define the obesity categories.
The Maestro Rechargeable System is the first obesity device to be approved by the FDA since 2007.
U.S. regulator approves first-of-kind device to treat obesity
"Obesity and its related medical conditions are major public health problems," said William Maisel, deputy director for science and chief scientist with the FDA's Center for Devices and Radiological Health, in a statement. "Medical devices can help physicians and patients to develop comprehensive obesity treatment plans."
The device, manufactured by EnteroMedics of St. Paul, Minnesota, consists of a rechargeable electrical pulse generator4, wire leads and electrodes implanted surgically6 into the abdomen7.
It works by sending intermittent8 electrical pulses to the trunks in the abdominal9 vagus nerve, which is involved in regulating stomach emptying and signaling to the brain that the stomach feels empty or full.
In a 12-month clinical trial that included 233 patients with a BMI of 35 or greater, those who received the active Maestro device lost 8.5 percent more of the excess weight than who received the device that was not activated10.
Serious adverse11 events reported in the clinical study included nausea12, pain at the neuroregulator site, vomiting13, as well as surgical5 complications. Other adverse events included pain, heartburn, problems swallowing, belching14, mild nausea and chest pain, the FDA said.
The clinical study did not meet its original goal, which was that those who received the active Maestro device lose at least 10 percent more excess weight than the control group.
However, the FDA said its advisory15 committee found the study supportive of sustained weight loss, and agreed that the benefits of the device outweighed16 the risks for use in patients.
As part of the approval, the company must conduct a five-year post approval study that will follow at least 100 patients and collect additional safety and effectiveness data including weight loss, adverse events, surgical revisions and explants and changes in obesity-related conditions, the agency added.
点击收听单词发音
1 obesity | |
n.肥胖,肥大 | |
参考例句: |
|
|
2 aged | |
adj.年老的,陈年的 | |
参考例句: |
|
|
3 diabetes | |
n.糖尿病 | |
参考例句: |
|
|
4 generator | |
n.发电机,发生器 | |
参考例句: |
|
|
5 surgical | |
adj.外科的,外科医生的,手术上的 | |
参考例句: |
|
|
6 surgically | |
adv. 外科手术上, 外科手术一般地 | |
参考例句: |
|
|
7 abdomen | |
n.腹,下腹(胸部到腿部的部分) | |
参考例句: |
|
|
8 intermittent | |
adj.间歇的,断断续续的 | |
参考例句: |
|
|
9 abdominal | |
adj.腹(部)的,下腹的;n.腹肌 | |
参考例句: |
|
|
10 activated | |
adj. 激活的 动词activate的过去式和过去分词 | |
参考例句: |
|
|
11 adverse | |
adj.不利的;有害的;敌对的,不友好的 | |
参考例句: |
|
|
12 nausea | |
n.作呕,恶心;极端的憎恶(或厌恶) | |
参考例句: |
|
|
13 vomiting | |
吐 | |
参考例句: |
|
|
14 belching | |
n. 喷出,打嗝 动词belch的现在分词形式 | |
参考例句: |
|
|
15 advisory | |
adj.劝告的,忠告的,顾问的,提供咨询 | |
参考例句: |
|
|
16 outweighed | |
v.在重量上超过( outweigh的过去式和过去分词 );在重要性或价值方面超过 | |
参考例句: |
|
|
17 obese | |
adj.过度肥胖的,肥大的 | |
参考例句: |
|
|